Business Context and Reporting Period
This Form 8-K is a current report filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on April 17, 2020, covering events occurring on April 15, 2020. The company is a Delaware corporation trading on the Nasdaq Capital Market under the symbol TROV.
Key Financial Metrics
The filing discloses the following specific financial obligation:
- Loan Amount: $305,000
- Lender: JPMorgan Chase Bank, N.A.
- Program: Paycheck Protection Program (PPP) under the CARES Act
- Interest Rate: 0.98% per annum
- Maturity Date: April 15, 2022
- Payment Terms: Interest payable monthly commencing November 15, 2022; principal due at maturity unless forgiven.
- Permitted Use of Funds: Payroll costs, rent, and utilities.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or total liquidity beyond this specific loan.
Material Changes
The primary material change is the entry into a material definitive agreement to secure a $305,000 loan. This creates a direct financial obligation for the registrant. The filing does not provide comparative financial data to assess changes in revenue or profitability versus prior periods.
Outlook, Risks, and Contingencies
Loan Forgiveness Contingency: Under the terms of the PPP, certain amounts of the loan may be forgiven if the funds are used for qualifying expenses as described in the CARES Act. The company intends to use the entire loan amount for such qualifying expenses.
Prepayment: The note may be prepaid at any time prior to maturity with no prepayment penalties.
The filing does not contain specific management commentary on future guidance, operational risks, or unusual items beyond the loan terms.
Investor Verification Checklist
- Verify the company name is Trovagene, Inc. (TROV), not Cardiff Oncology, Inc.
- Confirm the utilization of the $305,000 loan strictly for payroll, rent, and utilities to ensure eligibility for forgiveness.
- Monitor future filings for updates on the loan forgiveness status.
- Review the company's most recent 10-K or 10-Q for comprehensive liquidity and cash flow data not included in this 8-K.